Nine Masts Capital’s Blueprint Medicines BPMC Stock Holding History

Nine Masts Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,000	Closed	-$769K	–	83
2025 Q2	$769K	Buy	+6,000	New	+$623K	0.28%	41

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Nine Masts Capital's BPMC Position: Q3 2025 in Review

Nine Masts Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 6,000 shares — an estimated $769K sold.

Nine Masts Capital first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $769K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Nine Masts Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Nine Masts Capital sold 6,000 Blueprint Medicines shares in Q3 2025, an estimated $769K.
Nine Masts Capital first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
Nine Masts Capital's Blueprint Medicines position peaked at $769K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Nine Masts Capital's 13F filing for Q3 2025, filed 13 Nov 2025.